SSY GROUP (02005): Receives Production Registration Certificate for Benidipine Hydrochloride Tablets
Stock News
Aug 25
SSY GROUP (02005) announced that the group has obtained a drug production registration certificate from China's National Medical Products Administration (NMPA) for Benidipine Hydrochloride Tablets (8mg). The product is classified as a Category 4 chemical drug and is deemed to have passed consistency evaluation. Benidipine Hydrochloride Tablets are primarily used for treating primary hypertension and angina. As disclosed in the company's announcement dated January 6, 2025, the group's benidipine hydrochloride active pharmaceutical ingredient had already received NMPA approval for registration as an active ingredient for use in marketed formulations.
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.